Dr. Decker on Current Role of Radiation in NSCLC

Video

Roy Decker, MD, PhD, associate professor of Therapeutic Radiology, Yale Cancer Center, discusses the current role of radiation therapy in the treatment of patients with non–small cell lung cancer.

Roy Decker, MD, PhD, associate professor of Therapeutic Radiology, Yale Cancer Center, discusses the current role of radiation therapy in the treatment of patients with non—small cell lung cancer (NSCLC).

Due to the rise of more effective therapies than in previous years, patients are living longer, thus making the management of metastatic disease more important, Decker says. One of the newest indications for radiation is for patients with oligometastic disease—patients who have metastases at diagnosis or after therapy, but with limited sites of disease. Recent studies have shown a survival benefit when adding radiation, surgery, or ablative techniques to a limited number of metastatic sites, when patients have oligometastases, after first-line chemotherapy.

With immunotherapy and targeted agents, physicians are seeing patients recur at isolated sites of disease. These are patients who had several sites of metastases, but are now progressing in 1 or disease locations, Decker says. Aggressive local radiation is an option here, Decker says, so patients can continue to benefit from the systemic therapy they are responding to in other areas.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.